T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Srđan Verstovšek, Claire Harrison et al.|Haematologica|2016Cited by 85
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity ConditioningRan Reshef, David Porter, James K. Mangan et al.|Journal of Clinical Oncology|2015Cited by 60
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancerM. Ángela Aznar, Mark H. O’Hara, Charly R. Good et al.|Cell Reports Medicine|2025Cited by 12